z-logo
Premium
Bactericidal Activity of a Monoclonal Antibody Against a Recombinant 40‐kDa Outer Membrane Protein of Porphyromonas gingivalis
Author(s) -
Katoh Mitsunobu,
Saito Shigeno,
Takiguchi Hisashi,
Abiko Yoshimitsu
Publication year - 2000
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2000.71.3.368
Subject(s) - porphyromonas gingivalis , monoclonal antibody , microbiology and biotechnology , recombinant dna , bacterial outer membrane , antibody , chemistry , virulence , biology , bacteria , escherichia coli , immunology , gene , biochemistry , genetics
Background: We have cloned the gene for a 40‐kDa outer membrane protein (40‐kDa OMP) from Porphyromonas gingivalis 381. The recombinant (r)40‐kDa OMP has become the subject of considerable interest because of its potential role in the development of a vaccine useful for passive immunization. To develop such a vaccine, it is essential to fully understand the functions of anti‐r40‐kDa OMP antibody in the host defense against P. gingivalis. To that end, we developed a panel of monoclonal antibodies by immunizing mice with purified r40‐kDa OMP. The objective of this study was to determine the bactericidal activity on P. gingivalis by the IgG1 monoclonal antibody Pg‐ompA2. Methods: Bacterial growth measurement, a complementmediated anti‐P. gingivalis assay based on [ 3 H]thymidine uptake, and a 14C‐release assay were performed to test the bactericidal activity of Pg‐ompA2 to P. gingivalis. Results: In the presence of complement, Pg‐ompA2 was lethal to P. gingivalis 381 as well as to the more virulent P. gingivalis strains, including ATCC 53977 and W83. Using component‐defi‐cient complement, we determined that Pg‐ompA2 killed P. gingivalis by activating both the classical and alternative complement pathways. Conclusions: Pg‐ompA2 has an in vitro complement‐mediated bactericidal activity to P. gingivalis. Pg‐ompA2 may contribute to the development of a local immunotherapy that can be applied in the gingival crevice of a patient with P. gingivalis related periodontitis, or be a vaccine candidate. J Periodontol 2000;71:368‐375.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here